CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received an average rating of “Hold” from the eighteen brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $77.93.
Several research firms have weighed in on CRSP. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Chardan Capital reiterated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Barclays dropped their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Wednesday, December 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th.
Check Out Our Latest Analysis on CRISPR Therapeutics
CRISPR Therapeutics Price Performance
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same quarter in the previous year, the company earned ($1.41) earnings per share. Sell-side analysts anticipate that CRISPR Therapeutics will post -5.13 EPS for the current fiscal year.
Insiders Place Their Bets
In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This trade represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,382 shares of company stock valued at $2,744,179. 4.10% of the stock is currently owned by insiders.
Institutional Investors Weigh In On CRISPR Therapeutics
Several hedge funds have recently made changes to their positions in CRSP. Larson Financial Group LLC grew its stake in shares of CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in CRISPR Therapeutics during the 2nd quarter worth $35,000. Denver PWM LLC acquired a new stake in shares of CRISPR Therapeutics in the 2nd quarter worth $45,000. National Bank of Canada FI boosted its holdings in shares of CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after acquiring an additional 220 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics during the third quarter worth about $40,000. Institutional investors and hedge funds own 69.20% of the company’s stock.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Recommended Stories
- Five stocks we like better than CRISPR Therapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- 5 Top Rated Dividend Stocks to Consider
- How AI Implementation Could Help MongoDB Roar Back in 2025
- Expert Stock Trading Psychology Tips
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.